TriSalus Life Sciences (TLSI) has announced a strategic partnership with Geo-Med to expand availability of the TriNav Infusion System to U.S. Department of Veterans Affairs medical centers nationwide. Fittingly, on the day honoring our veterans, we announce this pivotal collaboration designed to expand access for U.S. veterans to our proprietary PressuMike Locke, Chief Executive Officer of Geo-Med, added, “We are proud to collaborate with TriSalus to bring this innovative delivery technology to veterans. Liver cancer is a particularly aggressive disease, and by expanding access to TriNav, we’re providing veterans with the latest advancements in treatment.” re-Enabled Drug Delivery approach. PEDD is enabled by TriNav, a promising technology with the potential to improve liver cancer outcomes,” said Mary Szela, Chief Executive Officer and President of TriSalus. “We are thrilled to partner with Geo-Med to increase access to TriNav for veterans battling liver cancer. This collaboration is closely aligned with our mission to enhance patient outcomes, particularly for those who have served our country.” …
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus Life Sciences initiated with a Buy at Roth MKM
- TriSalus Life Sciences files to sell 10.59M shares of common stock for holders
- TriSalus Life Sciences initiated with an Outperform at Northland
- TriSalus Life Sciences management to meet with Oppenheimer
- TriSalus: PEDD method via TriNav Infusion System aided penetration of GM